回盛生物 (300871.SZ)

15.37 -0.08 (-0.52%) 收市：02:45PM CST

回盛生物

No.208 Zhangbai Road
Dongxihu District
Wuhan 430042
China
86 27 8860 5516
https://www.whhsyy.com

版塊: Healthcare
行業: Biotechnology
全職員工: 1,068

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Weiyuan Zhang	Chairman & GM	無	無	1969
Mr. Jie Liu	Vice Chairman & Chief Scientist	無	無	1964
Mr. Kaijie Yang	Deputy GM & CFO	無	無	1970
Mr. Zexiang Liu	Director & Assistant to the GM	無	無	1976
Mr. Jie Han	Deputy General Manager	無	無	1985
Ms. Hongxia Li	Director of Warehousing & Logistics Data and Supervisor	無	無	1976
Ms. Jian Zhou	Chairman of the Supervisory Board & Assistant to the GM	無	無	1974
Mr. Wenge Ding	Product & Technical Service Director and Supervisor	無	無	1969

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CNY。

描述

Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives. Hvsen Biotechnology Co., Ltd. was founded in 2002 and is based in Wuhan, China.

公司管治

截至 無 止，回盛生物 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。